Compile Data Set for Download or QSAR
Report error Found 2116 Enz. Inhib. hit(s) with all data for entry = 9619
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305704(US10144734, Example 722 | 2-chloro-N-((3S,4S)-1-(5...)
Affinity DataIC50: 2nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305705(US10144734, Example 723 | 2-chloro-N-((3S,4S)-1-(5...)
Affinity DataIC50: 3nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305757(US10144734, Example 775 | 3-chloro-N-(1-(5-(3- cya...)
Affinity DataIC50: 3nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305765(US10144734, Example 783 | 2-chloro-N-(1-(5-(3- cya...)
Affinity DataIC50: 3nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305759(US10144734, Example 777 | 3-chloro-N-(1-(5-(3- cya...)
Affinity DataIC50: 3nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305672(US10144734, Example 690 | US10172845, Example 690 ...)
Affinity DataIC50: 3.70nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305468(US10144734, Example 485 | US10172845, Example 485 ...)
Affinity DataIC50: 3.70nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305752(US10144734, Example 770 | US10172845, Example 770 ...)
Affinity DataIC50: 4nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305724(US10144734, Example 742 | 4-(6-(4-(3-fluorobenzyl)...)
Affinity DataIC50: 4nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305707(US10144734, Example 725 | N-((3S,4S)-1-(5-(3-cyano...)
Affinity DataIC50: 4nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305355(US10144734, Example 371 | US10172845, Example 371 ...)
Affinity DataIC50: 4.20nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305346(US11648243, Example 362 | US10144734, Example 362 ...)
Affinity DataIC50: 4.40nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305687(US10144734, Example 705 | US10172845, Example 705 ...)
Affinity DataIC50: 4.60nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305789(US10144734, Example 807 | US10172845, Example 807 ...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305778(US10144734, Example 796 | 3-chloro-N-(1-(5-(3- cya...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305670(US10144734, Example 688 | US10172845, Example 688 ...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305712(US10144734, Example 730 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305776(US10144734, Example 794 | 2-chloro-N-(1-(5-(3- cya...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305171(4-(6-(3-(3,5- difluorophenoxy)azetidin- 1-yl)pyrid...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305662(US10144734, Example 680 | US10172845, Example 680 ...)
Affinity DataIC50: 5.20nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305071(US10144734, Example 87 | US10172845, Example 87 | ...)
Affinity DataIC50: 5.30nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305470(US10144734, Example 487 | US10172845, Example 487 ...)
Affinity DataIC50: 5.5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305347(US10144734, Example 363 | US10881652, Example 363)
Affinity DataIC50: 5.5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305367(US10144734, Example 384 | US10172845, Example 384 ...)
Affinity DataIC50: 5.70nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305152(4-(6-(3-(3- fluorophenoxy)azetidin- 1-yl)pyridin-3...)
Affinity DataIC50: 5.80nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305368(US10144734, Example 385 | US10172845, Example 385 ...)
Affinity DataIC50: 5.80nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305790(US10144734, Example 808 | (S)-N-(4-benzyl-1-(5-(3-...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305795(US10144734, Example 813 | (R)-N-(4-benzyl-1-(5-(3-...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305693(US10144734, Example 711 | 2-chloro-N-((3S,4S)-1-(5...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305579(US10144734, Example 597 | US10172845, Example 597 ...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305675(US10144734, Example 693 | US10172845, Example 693 ...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305738(US10144734, Example 756 | 6-ethoxy-4-(6-(4-(3- flu...)
Affinity DataIC50: 6nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305683(US10144734, Example 701 | US10172845, Example 701 ...)
Affinity DataIC50: 6.10nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305680(US10144734, Example 698 | US10172845, Example 698 ...)
Affinity DataIC50: 6.10nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305285(US11648243, Example 301 | US10144734, Example 301 ...)
Affinity DataIC50: 6.10nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305417(3-chloro-N-(1-(5-(3- cyano-6- methoxypyrazolo[1,5-...)
Affinity DataIC50: 6.20nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305029(US10144734, Example 45 | US10172845, Example 45 | ...)
Affinity DataIC50: 6.30nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305638(US10144734, Example 656 | US10172845, Example 656 ...)
Affinity DataIC50: 6.30nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305511(US10144734, Example 528 | US10172845, Example 528 ...)
Affinity DataIC50: 6.40nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305376(US10144734, Example 393 | US10172845, Example 393 ...)
Affinity DataIC50: 6.40nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305633(US10144734, Example 651 | US10172845, Example 651 ...)
Affinity DataIC50: 6.5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305318(US11648243, Example 334 | US10144734, Example 334 ...)
Affinity DataIC50: 6.60nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305302(US11648243, Example 318 | US10144734, Example 318 ...)
Affinity DataIC50: 6.60nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305374(US10144734, Example 391 | US10172845, Example 391 ...)
Affinity DataIC50: 6.70nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305026(US10144734, Example 42 | US10172845, Example 42 | ...)
Affinity DataIC50: 6.70nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305283(US11648243, Example 299 | US10144734, Example 299 ...)
Affinity DataIC50: 6.80nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305398(US10144734, Example 415 | US10172845, Example 415 ...)
Affinity DataIC50: 6.90nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305736(US10144734, Example 754 | 4-(6-(4-((5-fluoropyridi...)
Affinity DataIC50: 7nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

Displayed 1 to 50 (of 2116 total ) | Next | Last >>
Jump to: